The effect of statins and fibrates on interferon-γ and interleukin-2 release in patients with primary type II dyslipidemia

Atherosclerosis

Volumn 176, Issue 2, 2004, Pages 327-335

  Okopień, Boguslaw ^a   Krysiak, Robert ^a   Kowalski, Jan ^a   Madej, Andrzej ^a   Belowski, Dariusz ^a   Zieliński, Marek ^a   Labuzek, Krzysztof ^a   Herman, Zbigniew S ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Dyslipidemia; Fibrates; Interferon ; Interleukin 2; Lymphocytes; Statins

Indexed keywords

CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 2; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DYSLIPIDEMIA; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROBABILITY; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ARTERIOSCLEROSIS; CLOFIBRIC ACID; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INTERFERON TYPE II; INTERLEUKIN-2; MALE; MIDDLE AGED; PPAR ALPHA; T-LYMPHOCYTES;

EID: 5644241067     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.05.009     Document Type: Article

References (34)

1. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1998;115-126
2. Young J.L., Libby P., Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost. 88:2002;554-567
3. Reape T.J., Groot P.H. Chemokines and atherosclerosis. Atherosclerosis. 147:1999;213-225
4. Ferro D., Parrotto S., Basili S., Alessandri C., Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J. Am. Coll. Cardiol. 36:2000;427-431
5. Inoue I., Goto S., Mizotani K., et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 67:2000;863-876
6. Rezaie-Majd A., Maca T., Bucek R.A., et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 22:2002;1194-1199
7. Wahre T., Damas J.K., Gullestad L., et al. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J. Am. Coll. Cardiol. 41:2003;1460-1467
8. Youssef S., Stuve O., Patarroyo J.C., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 420:2002;78-84
9. Meroni P.L., Raschi E., Testoni C., et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 44:2001;2870-2878
10. Olsson A.G., Schwartz G.G., Jonasson L., Linderfalk C. Are early clinical effects of cholesterol lowering mediated through effects on inflammation? Acta Physiol. Scand. 176:2002;147-150
11. Zhao S.P., Ye H.J., Zhou H.N., Nie S., Li Q.Z. Gemfibrozil reduces release of tumor necrosis factor-alpha in peripheral blood mononuclear cells from healthy subjects and patients with coronary heart disease. Clin. Chim. Acta. 332:2003;61-67
12. Xu X., Otsuki M., Saito H., et al. PPARalpha and GR differentially down-regulate the expression of nuclear factor-kappaB-responsive genes in vascular endothelial cells. Endocrinology. 142:2001;3332-3339
13. Staels B., Koenig W., Habib A., et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 393:1998;790-793
14. Koh K.K., Son J.W., Ahn J.Y., et al. Comparative effects of diet and statin on NO bioactivity and matrix. metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 22:2002;e19-e23
15. Weis M., von Scheidt W. Coronary artery disease in the transplanted heart. Annu. Rev. Med. 51:2000;81-100
16. Miller D.B., Spence J.D. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokinet. 34:1998;155-162
17. Geng Y., Holm J., Nygren S., Bruzelius M., Stemme S., Hansson G.K. Expression of the macrophage scavenger receptor in atheroma: relationship to immune activation and the T-cell cytokine interferon-gamma. Arterioscler. Thromb. Vasc. Biol. 15:1995;1995-2002
18. Le Moine A., Goldman M., Abramowicz D. Multiple pathways to allograft rejection. Transplantation. 73:2002;1373-1381
19. Kowalski J., Blada P., Kucia K., et al. In vitro immunomodulatory effects of haloperidol and perazine in schizophrenia. World J. Biol. Psychiatry. 1:2000;190-196
20. Kwak B., Mulhaupt F., Veillard N., Pelli G., Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med. Wkly. 131:2001;41-46
21. Sadeghi M.M., Tiglio A., Sadigh K., et al. Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation. 71:2001;1262-1268
22. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6:2000;1399-1402
23. Horimoto H., Nakai Y., Nakahara K., Nomura Y., Mieno S., Sasaki S. HMG-CoA reductase inhibitor cerivastatin prolonged rat cardiac allograft survival by blocking intercellular signals. J. Heart Lung Transplant. 21:2002;440-445
24. Stanislaus R., Pahan K., Singh A.K., Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci. Lett. 269:1999;71-74
25. Stanislaus R., Gilg A.G., Singh A.K., Singh I. Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by lovastatin. Neurosci. Lett. 333:2002;167-170
26. Kurakata S., Kada M., Shimada Y., Komai T., Nomoto K. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology. 34:1996;51-61
27. Zubelewicz-Szkodzinska B., Szkodzinski J., Danikiewicz A., et al. Effects of simvastatin on pro-inflammatory cytokines in patients with hypercholesterolemia. Kardiol. Pol. 59:2003;465-474
28. Marx N., Kehrle B., Kohlhammer K., et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res. 90:2002;703-710
29. Madej A., Okopien B., Kowalski J., et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int. J. Clin. Pharmacol. Ther. 36:1998;345-349
30. Melenovsky V., Malik J., Wichterle D., et al. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am. Heart J. 144:2002;G1-G8
31. Lennernas H., Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 32:1997;403-425
32. Liao J.K. Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110:2002;285-288
33. Mueck A.O., Seeger H. Statins and direct vascular actions. Panminerva Med. 45:2003;1-6
34. Weis M., Pehlivanli S., Meiser B.M., von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J. Am. Coll. Cardiol. 38:2001;814-818